secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-05-14T11:34:46+00:00
Accession:  0001410098-26-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance
----------------------------------------------------------------------

- Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.
- DefenCath revenue $97.5M (incl. $9.0M favorable estimate change); Melinta portfolio $29.9M.
- Raises FY2026 guidance: net revenue $325-345M, adjusted EBITDA $115-135M.
- Positive Phase III topline for REZZAYO prophylaxis; sNDA submission H2 2026, potential launch 2027.
- Cash and investments $178.1M; TPN study trending to 2028, actions to accelerate enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/0001410098-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001410098-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer